1. Melton R, Thomas R. Corticosteroids. In: Melton R, Thomas R. 2001 Clinical Guide to Ophthalmic Drugs. Rev Optom suppl. 2001 May:18A-21A.
2. Skorin L. Uses and effects of ocular steroids. Rev Optom 2002 May;139(5):85-92.
3. Jaanus SD, Lesher GA. Anti-Inflammatory Drugs. In: Bartlett JD, Jaanus SD (eds). Clinical Ocular Pharmacology. Boston: Butterworth-Heineman, 1995:303-336.
4. Foster SC. Topical Steroid Treatment of Ocular Inflammation. In: Advances in Ocular Pharmacology, Ophthalmology Clinics of North America 1997 Sept;10(3):389-403.
5. Leibowitz HM, Kupperman A. Uses of Corticosteroids in the Treatment of Corneal Inflammation. In Leibowitz HM (ed). Corneal Disorders, Clinical Diagnosis and Management. Philadelphia: . Saunders, 1984:286-307.
6. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992 Jul;10(3):505-12.
7. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs and Aging 1999;15(6)439-450.
8. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11:478-483.
9. Whitcup SM, Ferris FL 3rd. New corticosteroids for the treatment of ocular inflammation. Am J Ophthalmol 1999 May;127(5):597-9.
10. Giles, CL, Mason GL, Duff IF, et al. The association of cataract formation and systemic corticosteroid therapy. JAMA 1962;182:719.
11. Urban RC, Cotlier E. Corticosteroid Induced Cataracts. Surv Ophthalmol 1986;31:102-110.
12. Anti-Inflammatory Agents. In: Bartlett JD (ed). Ophthalmic Drug Facts. St. Louis: Wolters Kluwer Health, 2005:87-99.
13. Reddy IK, Ganesan MG. Ocular Therapeutics and Drug Delivery: An Overview. In: Reddy ID (ed). Ocular Therapeutics and Drug Delivery: A Multidisciplinary Approach. Lancaster, Pa.: Technomic Publishing Co., 1996:3-29.
14. Howes JF. Development of Soft Drugs for Ophthalmic Use. In: Ocular Therapeutic and Drug Delivery: A Multidisciplinary Approach. Lancaster, Pa.: Technomic Publishing Co., 1996:363-374.
15. Foster CS, Alter G, DeBarge LR, et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996 Aug; 122(2):171-82.
16. Nader N. Therapeutic effect of generic drug not always equal to brand. Ocular Surgery News 2002;20(11):47.
17. Wittpenn JR. Generic versus brand name drugs. Therapeutic Updates in Ophthalmology 2003;5(1):3.
18. Fiscella RG. Generic prednisolone suspension substitution. Arch Ophthalmol 1998 May;116(5):703.
The obvious priority is immediate discontinuation of any further topical corticosteroid use. Protection and support of the impaired skin barrier is another priority. Eliminating harsh skin regimens or products will be necessary to minimize potential for further purpura or trauma, skin sensitivity, and potential infection. Steroid Atrophy   is often permanent, though if caught soon enough and the topical corticosteroid discontinued in time, the degree of damage may be arrested or slightly improve. However, while the accompanying Telangectasias may improve marginally, the Striae is permanent and irreversible. 
The doctor may suggest hospitalization simply because it may be necessary to break the cycle of chronic inflammation, or other problems that are exacerbating the illness. Frequently, five or six days of vigorous in-hospital treatment care can result in a dramatic clearing of the eczema. Food tests, allergy skin testing, and the development of an outpatient therapy plan can all be done during the hospitalization. Unfortunately, getting approval from insurers is often difficult. During an acute flare the number of 15-20 minute baths must be increased to three or four per day. Besides hydrating the skin, baths also increase the penetration of topical medication up to ten-fold if the medicine is applied immediately after the bath. Wet wraps after baths may also help hydration and medicinal penetration. Bedtime wet wraps are most practical, and can be done with elasticized gauze followed by ace bandages or double pajamas. (The first pair of pajamas is worn damp but not soaking wet, and a second pair of dry pajamas is worn over them. For a tighter fit, sometimes a plastic sauna suit is used instead of the dry pajamas.) For feet and hands, socks can be used. Additional blankets or increased room heat may be necessary during this three to seven days to prevent chilling.